Excelitas Technologies Acquires Phoseon Technology, Strengthening Their Established UV Curing Capabilities and Expanding LED Innovation

With market-leading LED innovation and field-proven reliability, Phoseon adds further energyefficient alternatives in UV lighting solutions across industrial curing, scientific illumination and non-contact UVC disinfection to Excelitas’ extensive illumination technologies portfolio.

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Excelitas Technologies® Corp., a leading industrial technology manufacturer focused on delivering innovative, market-driven photonic solutions, completed the acquisition of Phoseon Technology, Inc, Hillsboro, OR, USA on February 15, 2023. Phoseon is an established pioneer in the design and manufacture of world-class LED-based industrial curing and scientific illumination solutions delivering field-proven reliability and enabling significant efficiency gains for a wide range of global customers. “I am delighted to welcome the Phoseon team to the Excelitas family. Phoseon’s core capabilities in LED innovation and manufacturing ideally complement our existing technology offering and provide an excellent opportunity for expanded R&D cooperation to better serve our customers,” said Paul Brierley, Vice President Lighting at Excelitas Technologies. “Furthermore, Phoseon’s compelling standard product portfolio promises tremendous growth when combined with our expansive global channel sales network. We are enthused with the prospect of offering the markets our extensive reach and broader range of UV LED solutions,” Brierley concluded. Phoseon joins Excelitas’ commercial business unit and will continue to operate from its state-ofthe-art headquarters in Hillsboro, OR, extending Excelitas’ geographic footprint into the Pacific Northwest. “Phoseon’s market strength in UV curing for the printing, coatings and finishing sectors is a perfect fit with Excelitas’ proven leadership in UV curing for the medical device and electronics manufacturing space. Together, we offer comprehensive sales and support for curing solutions across the broadest possible range of applications,” said Bill Cortelyou, President and CEO of Phoseon Technology. “We are extremely pleased with the strong support and seamless integration that this partnership will create. We see increased LED and UV innovation forthcoming and expect significant growth in this new partnership,” Cortelyou added. The acquisition of Phoseon is the latest in a series of strategic acquisitions by Excelitas Technologies since its founding in 2010. It is the fifth such acquisition since Excelitas was acquired by AEA Investors (New York, NY, USA) in December 2017.

You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
TS Digest January 2025
January 2025, Issue 1

Why Do Some People Get Drunk Faster Than Others?

Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.

View this Issue
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo
New Frontiers in Vaccine Development

New Frontiers in Vaccine Development

Sino
New Approaches for Decoding Cancer at the Single-Cell Level

New Approaches for Decoding Cancer at the Single-Cell Level

Biotium logo
Learn How 3D Cell Cultures Advance Tissue Regeneration

Organoids as a Tool for Tissue Regeneration Research 

Acro 

Products

Artificial Inc. Logo

Artificial Inc. proof-of-concept data demonstrates platform capabilities with NVIDIA’s BioNeMo

Sapient Logo

Sapient Partners with Alamar Biosciences to Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines, and Inflammatory Mediators

Bio-Rad Logo

Bio-Rad Extends Range of Vericheck ddPCR Empty-Full Capsid Kits to Optimize AAV Vector Characterization

Scientist holding a blood sample tube labeled Mycoplasma test in front of many other tubes containing patient samples

Accelerating Mycoplasma Testing for Targeted Therapy Development